BrianAndrewVan TineMD
Oncology • Saint Peters, MOHematologic Oncology, Sarcoma
Instructor, Internal Medicine, Washington University School of Medicine
Dr. Van Tine is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
150 Entrance Way
# Dv
Saint Peters, MO 63376Phone+1 800-647-2098Fax+1 314-362-3192
Summary
- I have set out on a lifelong mission to make an impact in the treatment of patients with sarcoma. I spent the first three years of my career developing a very large and robust trials-based sarcoma program at Washington University in St. Louis. This is now the largest program in the Midwest, and I have been the PI of over 40 clinical trials. I was awarded an early career development grant by the Sarcoma Alliance through Research and Collaboration.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2007 - 2011- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2005 - 2007
University of Alabama School of MedicineClass of 2005
Certifications & Licensure
OH State Medical License Current
IL State Medical License 2020 - 2026
MO State Medical License 2007 - 2026- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
Clinical Trials
- Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma Start of enrollment: 2021 Jan 05
- 89Zr-Trastuzumab PET/CT in Subjects With Previously Treated HER2-Positive Solid Tumors Scheduled to Receive Treatment With MT-5111 Start of enrollment: 2021 Dec 31
- Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 2020 Jan 14
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 2 citationsA Single-Arm Phase II Trial of Sitravatinib in Advanced Well-Differentiated/Dedifferentiated Liposarcoma.Matthew Ingham, Shing Lee, Brian A Van Tine, Edwin Choy, Jay Oza
Clinical Cancer Research. 2023-03-14 - 71 citationsHistopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness.Yize Li, Tung-Shing M Lih, Saravana M Dhanasekaran, Rahul Mannan, Lijun Chen
Cancer Cell. 2023-01-09 - 39 citationsOlutasidenib (FT-2102) in patients with relapsed or refractory IDH1-mutant glioma: A multicenter, open-label, phase Ib/II trial.Macarena I de la Fuente, Howard Colman, Mark Rosenthal, Brian A Van Tine, Danijela Levacic
Neuro-Oncology. 2023-01-05
Lectures
- A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in subjects with HER-2 p...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.2019 ASCO Annual Meeting - 6/1/2019
- Emerging Agents: Metabolism, DNA Repair, and Hypoxia2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Committees
- Member, NRG Sarcoma Committee 2014 - Present
Research History
- Sarcoma Alliance for Research2012 - 2015
Professional Memberships
- Sarcoma Working Group of AllianceCo-Chair
- Sarcoma Survivorship working group of SWOGMember
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
